Treace Medical Concepts, Inc. is a medical technology company that designs, manufactures, and sells orthopaedic medical devices for the surgical management of bunion and related midfoot deformities. The company's primary product is the Lapiplasty 3D Bunion Correction System, a patented combination of instruments, implants, and surgical methods intended to correct three-dimensional bunion deformities and secure the unstable first tarsometatarsal joint. Its portfolio also includes the Adductoplasty Midfoot Correction System, the Nanoplasty 3D Minimally Invasive Bunion Correction System, the Percuplasty Percutaneous 3D Bunion Correction System, and the SpeedMTP System for great toe fusions. Treace offers the SpeedPlate rapid compression implant platform, SuperBite fully-threaded compression screws, and the IntelliGuide patient-specific pre-op planning and cut guide technology. The company markets and sells its products primarily in the United States through a direct employee sales force and independent sales agencies, serving surgical podiatrists and orthopaedic surgeons with foot and ankle specializations. Treace also provides surgeon education, training, and a direct-to-patient outreach program to support the adoption of its surgical systems.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage treace.com
Sector Healthcare IR page investors.treace.com
Tags
orthopaedic devices, bunion correction, midfoot correction, surgical instruments, implants, minimally invasive surgery, foot and ankle, pre-op planning, Lapiplasty 3D Bunion Correction System, Adductoplasty Midfoot Correction System, Nanoplasty 3D Minimally Invasive Bunion Correction System, Percuplasty Percutaneous 3D Bunion Correction System, SpeedMTP System, SpeedPlate Rapid Compression Implant, IntelliGuide, SuperBite Fully-Threaded Compression Screws
Press page —

Metrics

Valuation  
Market cap $ 291.085M
Market cap (USD) $ 291.085M
P/E -5.22
PEG —
P/BV 4.72
P/S 1.43
P/OCF -33.31
P/FCF -15.67
Dividend yield —
Turnover / mcap —
Returns  
ROE -58.9%
ROI -40.8%
ROIC -28.1%
Profit margin -27.7%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 91.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 6
Quality score -35.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 212.69M 209.357M 187.118M 141.838M 94.419M 57.365M
Net profit -59.002M -55.743M -49.527M -42.815M -20.552M -3.668M
Free cash flow -29.487M -48.76M -46.033M -45.486M -19.898M -5.563M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 2.45 7.44 12.75 22.99 18.64 —
Price performance 12m -0.67 -0.42 -0.45 0.23 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 14.5M 18.6M 29.2M 38.1M 40.8M 42.2M
↳ YoY growth +28.2% +57.2% +30.4% +7.2% +3.3%
↳ 5y CAGR +23.8%
Borrowings, current (USD) — — 1.79M — — — 0.00 1.75M
Borrowings, non-current (USD) — — 29.2M 29.4M 52.7M 53M 53.3M 55.6M
Lease liabilities (USD) — — — 0.00 15.9M 17.3M 16.3M 14.5M
Cash and deposits (USD) 1.28M 12.1M 18.1M 106M 19.5M 13M 11.4M 10.7M
Intangible assets (USD) — — — — 0.00 9.03M 8.08M 7.13M
Right-of-use assets (USD) — — — 0.00 10.1M 9.26M 8.44M 7.61M
Net debt (borrowings + leases - cash) (USD) — — 12.9M -76.5M 49.1M 57.3M 58.3M 61.2M
Cash flow detail
Operating cash flow (USD) — -7.67M -4.49M -17.2M -30.6M -34.6M -37.2M -16M
Purchases of property, plant and equipment (USD) — -1.21M -1.07M -2.71M -14.8M -11.5M -11.6M -13.5M
Change in receivables (cash effect) (USD) — -6.02M -4.29M -4.23M -11M -9.3M -5.69M -2.09M
Change in inventories (cash effect) (USD) — -2.81M -3.4M -3.09M -8.77M -9.85M -10M 3.22M
Change in payables (cash effect) (USD) — -236,000 1.33M 1.79M 4.61M 3.17M -1.31M -3.8M
Interest paid (cash effect) (USD) — -739,000 -1.15M -3.9M -4.4M -5.17M -4.96M -5M
Share-based compensation (USD) — 815,000 919,000 3.41M 8.11M 17.4M 30.6M 33.8M
Operating cash flow before change in receivables (USD) — -1.65M -204,000 -13M -19.6M -25.3M -31.5M -13.9M
Free cash flow (OCF - PPE - intangibles) (USD) — -8.88M -5.56M -19.9M -45.5M -46M -48.8M -29.5M
Income detail
Research and development expense (USD) — 5.07M 5.85M 10.2M 13.6M 15.4M 20.6M 20.3M
↳ 5y CAGR +32.4% +28.2%
Total comprehensive income (USD) — — -4.31M -20.7M -42.8M -49.3M -55.8M -59M
Comprehensive income to owners (USD) — — -4.31M -20.7M -42.8M -49.3M -55.8M -59M
Provision for credit losses (USD) — 145,000 216,000 144,000 411,000 434,000 2.95M 700,000
Credit cost ratio (credit losses / average receivables) (%) — — — 0.9% 1.7% 1.3% 7.5% 1.7%
Reported Mar 4, 2022 Mar 4, 2022 Mar 8, 2023 Mar 8, 2023 Aug 9, 2023 Feb 27, 2024 May 8, 2025 Feb 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Achieved double digit procedure volume growth in the third quarter

PONTE VEDRA, Fla. – November 6, 2026 – Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company with the goal of being the recognized leader in the surgical treatment of bunions and other foot & ankle conditions, today reported financial results for the third quarter ended September 30, 2026.

Recent Highlights

•Generated revenue of $48.3 million in the third quarter 2026.

•Improved third quarter 2026 net loss by 23% to $(12.6) million, and Adjusted EBITDA by $2.9 million to $0.3 million when compared to the prior year period.

•Reduced year-to-date cash usage by 53% or $9.7 million when compared to the same period in 2025. Cash, cash equivalents, and marketable securities totaled $39.8 million as of September 30, 2026.

•Announced 5-Year results of a prospective, multicenter study demonstrating long term, positive outcomes of the Lapiplasty® procedure; a first-in-industry milestone for a commercial instrumented bunion correction system.

PONTE VEDRA, Fla. – August 7, 2026 – Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related deformities, today reported financial results for the second quarter ended June 30, 2026.

Recent Highlights

•Generated revenue of $45.4 million in the second quarter 2026 compared to $47.4 million in the same period in 2025.

•Reported second quarter 2026 net loss of $(15.9) million and adjusted EBITDA of $(3.5) million in the second quarter 2026.

•Reduced year-to-date cash usage by 57% or $3.6 million when compared to the same period in 2025. Cash, cash equivalents, and marketable securities totaled $45.6 million as of June 30, 2026.

•Initiated limited market release of SuperBite™ Compression Screw System and completed the first surgical case with HyperPlate™ XM Dynamic Compression Locking Implant System.

•Increased adoption of expanded bunion portfolio with approximately 40% of Lapiplasty® surgeon users incorporating one or more of its three new bunion systems launched in the third quarter 2025 from 35% in the first quarter of 2026.

At the 2026 Annual Meeting of Stockholders (the "Meeting") of Treace Medical Concepts, Inc. (the "Company") held on May 19, 2026, the stockholders of the Company voted on the following proposals, each of which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 6, 2026. The results of voting on the three proposals, including final voting tabulations, are set forth below. Proposal 1: Election of Directors. The stockholders elected, by the votes indicated below, the following nominees to the Company’s Board of Directors to serve as Class II directors for a three-year term of office expiring at the 2029 annual meeting of stockholders or until their respective successors have been duly elected and qualified:

Name

For

Withheld

Broker Non-Vote

Lance A. Berry

33,804,407

820,723

13,516,432

Elizabeth S. Hanna

30,856,965

3,768,165

13,516,432

Jane E. Kiernan

33,587,226

1,037,904

13,516,432

Proposal 2: Advisory Vote on Executive Compensation.

Prompts

Treace Medical Concepts, Inc. (ticker TMCI), listed in United States.

ETFs Holding Treace Medical Concepts, Inc.

ETF Weight in ETF Shares Market value As of
DFAS 0.00% 61,590 $ 328.891K Nov 12, 2026
AVSC 0.00% 8,106 $ 35.829K Nov 16, 2026